📌 Quick Answer: How do you value a startup with no revenue?
Pre-revenue startups are valued using qualitative and probability-weighted methods rather than traditional DCF or earnings multiples. The three most defensible frameworks are the Berkus Method (risk-dimension scoring up to INR 4 crore per factor), the Scorecard Method (comparative benchmarking against funded peers), and Revenue Ramp Bayesian analysis (probability-weighted scenario modelling). They were never prescribed methods under Rule 11UA of the Income Tax Rules, and the angel-tax clause that rule served, Section 56(2)(viib), does not apply from Assessment Year 2025-26. Today they serve as internationally used venture methods in two places: a pricing certificate for a foreign investor under rule 21 of the FEMA Non-Debt Instrument (NDI) Rules, which accepts any internationally accepted pricing methodology on an armβs length basis certified by a Chartered Accountant, SEBI-registered Merchant Banker or practising Cost Accountant, and the report of an IBBI Registered Valuer for a preferential allotment under Section 62(1)(c) of the Companies Act, 2013. At Virtual Auditor, we have issued over 200 pre-revenue valuation certificates across SaaS, deep-tech, and D2C verticals β book a consultation to discuss your round.
📖 Definition β Pre-Revenue Startup: A company that has developed a product or service concept β and may have a prototype, beta users, or letters of intent β but has not yet generated recurring commercial revenue. The absence of revenue makes traditional valuation approaches (DCF, revenue multiples, earnings multiples) either inapplicable or highly speculative.
📖 Definition β Fair Market Value (Rule 11UA): Rule 11UA of the Income Tax Rules, 1962 fixes the fair market value of unquoted equity shares by prescribed methods. For Section 56(2)(x) (shares received for less than fair market value, taxed in the recipientβs hands) it is the net-asset-value formula in Rule 11UA(1)(c)(b). For the former angel tax under Section 56(2)(viib), Rule 11UA(2) allowed the net-asset-value formula or a DCF valuation by a SEBI-registered Merchant Banker and, from 25 September 2023, five further Merchant Banker methods for non-resident investors. The Finance Act, 2023 extended Section 56(2)(viib) to non-resident investors from Assessment Year 2024-25, and under the Finance (No. 2) Act, 2024 the clause does not apply from Assessment Year 2025-26.
📖 Definition β FEMA NDI Rules: The Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 govern pricing of equity instruments issued to non-resident investors. Rule 21 read with Schedule I prescribes that the price of shares issued to a person resident outside India shall not be less than the fair value certified by a Chartered Accountant, a SEBI-registered Merchant Banker or a practising Cost Accountant as per any internationally accepted pricing methodology on an arm’s length basis.
Every valuation methodology ultimately derives enterprise value from expected future cash flows, comparable transactions, or net asset values. When a company has operating revenue β even a single quarter of recognised sales β the valuer has an anchor: multiply the revenue by a sector multiple, project growth with some empirical basis, or discount observable cash flows. Pre-revenue startups offer none of these anchors. That is where pre-revenue startup valuation relies on DCF on projected cash flows, comparable transactions and venture-capital or Berkus methods.
The fundamental challenge is threefold:
At our practice, we address this tension by using multiple pre-revenue methods, triangulating results, and documenting the rationale for the chosen value with regulatory-grade rigour. This approach has withstood scrutiny in Income Tax assessments, FEMA audits, and NCLT proceedings. To see how the Berkus, Scorecard and Venture Capital approaches work, read about pre-revenue startup valuation methods.
Rule 11UA is the primary valuation rule for income tax purposes. Up to Assessment Year 2024-25 it applied when shares were issued at a premium under Section 56(2)(viib) (the angel tax provision, which does not apply from Assessment Year 2025-26). It still applies under Section 56(2)(x), when shares are received for less than fair market value. The rule prescribed these methods for unquoted equity shares:
The Finance Act, 2023 (effective AY 2024-25) extended Section 56(2)(viib) to shares issued to non-residents, so for that one year Rule 11UA(2) applied to resident and non-resident investors alike, while FEMA pricing continued to apply separately to non-residents. Apart from the net-asset formula, a Rule 11UA(2) valuation had to come from a SEBI-registered Merchant Banker. An IBBI Registered Valuer was not an eligible signer under that rule; a Registered Valuerβs report is what the Companies Act, 2013 requires for a preferential allotment (Section 62(1)(c), Section 247 and Rule 13 of the Companies (Share Capital and Debentures) Rules, 2014).
Additionally, the DPIIT Notification dated 19 February 2019 (as amended) exempted DPIIT-recognised startups from angel tax provisions under Section 56(2)(viib) β allowing them to issue shares at any premium to eligible investors without triggering deemed income. This exemption, which was extended through various notifications, was complemented by the broader abolition of angel tax effective from Assessment Year 2025-26 under the Finance (No. 2) Act, 2024. For a detailed analysis of the residual issues after angel tax abolition, see our article on Angel Tax Abolition: Residual Issues.
When a startup issues shares to a foreign investor (FDI), pricing must comply with FEMA NDI Rules. The relevant provisions are:
IBBI Registered Valuers (Securities or Financial Assets class) are authorised to issue valuation reports under the Companies Act, 2013, and the Insolvency and Bankruptcy Code, 2016. They were not eligible signers for a Rule 11UA(2) DCF valuation, which required a SEBI-registered Merchant Banker. The IBBI requires registered valuers to exercise independent professional judgement, document methodology selection rationale, perform sensitivity analysis, and comply with the Valuation Standards issued by IBBI. CA V. Viswanathan (IBBI/RV/03/2019/12333) is registered under the Securities or Financial Assets class and has issued pre-revenue valuation reports that have been accepted in Income Tax scrutiny proceedings, FEMA compliance audits, and investor due diligence reviews.
The Berkus Method was developed by Dave Berkus, an American angel investor and venture capitalist, in the mid-1990s. It was designed specifically for pre-revenue startups where traditional financial metrics are unavailable. The core insight is that value at the pre-revenue stage is driven by risk reduction rather than financial performance. Each milestone that a startup achieves β assembling a team, building a prototype, securing a customer letter of intent β reduces a specific category of risk, and that risk reduction has quantifiable value.
The method was originally calibrated for US startups with a maximum pre-money valuation of USD 2 million (approximately INR 16 crore at current rates). In our practice, we recalibrate the maximum per-dimension value for the Indian context based on sector, geography, and the current funding environment.
The Berkus Method assigns a value of zero to a maximum cap for each of five risk dimensions. The original US framework caps each at USD 500,000; in our Indian practice, we use sector-specific caps, typically ranging from INR 1 crore to INR 4 crore per dimension depending on the addressable market size and the stage of the ecosystem.
| Risk Dimension | What It Measures | Evidence Required | Typical Indian Cap (INR Cr) |
|---|---|---|---|
| Sound Idea (Basic Value) | Is the business concept addressing a real, identifiable market need? | Market research, TAM/SAM/SOM analysis, problem-solution fit documentation | 1.0 β 3.0 |
| Prototype / Technology | Has the team built a working prototype or minimum viable product? | Working demo, beta product, patent applications, technical architecture documents | 1.0 β 4.0 |
| Quality Management Team | Does the founding team have domain expertise, execution track record, and complementary skills? | Founder CVs, prior exits, domain experience, advisory board composition | 1.5 β 4.0 |
| Strategic Relationships | Has the startup secured distribution partnerships, letters of intent, or anchor customer commitments? | Signed LOIs, partnership MOUs, pilot programme agreements, channel partner commitments | 0.5 β 3.0 |
| Product Rollout / Sales | Has the product been launched or are there early (non-recurring) sales signals? | Beta user metrics, wait-list data, pre-orders, early-adopter engagement data | 0.5 β 3.0 |
Step 1 β Define sector-appropriate caps. We begin by identifying 10β15 comparable startups in the same sector and geography that raised pre-seed or seed funding in the preceding 18 months. The median pre-money valuation of these comparables sets the aggregate cap. For example, if the median pre-seed valuation for Indian B2B SaaS companies is INR 12 crore, the aggregate Berkus cap is INR 12 crore, distributed across the five dimensions based on their relative importance in that sector.
Step 2 β Score each dimension. We assign a score from 0% to 100% for each dimension based on the evidence provided by the founder and verified through our due diligence. A score of 0% means the risk is entirely unmitigated (e.g., no prototype exists). A score of 100% means the risk is fully mitigated (e.g., a working product with demonstrated technical feasibility and IP protection).
Step 3 β Calculate dimension values. Each dimension’s value equals the score multiplied by the sector-specific cap for that dimension. The sum of all five dimension values is the pre-money enterprise value.
Step 4 β Cross-validate. We cross-check the Berkus output against recent comparable transactions and, where possible, against a simplified probability-weighted DCF. If the Berkus value is more than 1.5 standard deviations from the comparable median, we re-examine and document the rationale for the deviation.
Consider a deep-tech startup building an AI-powered quality inspection system for automotive manufacturing. The company has no revenue but has a working prototype deployed at one factory on a pilot basis. The founding team includes two IIT alumni with 15 years of combined experience in computer vision and one co-founder from the automotive industry.
| Dimension | Cap (INR Cr) | Score | Value (INR Cr) |
|---|---|---|---|
| Sound Idea | 2.5 | 85% | 2.13 |
| Prototype / Technology | 3.5 | 75% | 2.63 |
| Quality Management Team | 3.5 | 80% | 2.80 |
| Strategic Relationships | 2.0 | 40% | 0.80 |
| Product Rollout / Sales | 2.5 | 30% | 0.75 |
| Total Pre-Money Valuation | 9.11 | ||
The Berkus Method yields a pre-money valuation of approximately INR 9.1 crore. This aligns with the pre-seed range for Indian deep-tech startups with working prototypes and strong teams. The relatively low scores on Strategic Relationships and Product Rollout reflect the early stage β the pilot is not yet a commercial contract, and no distribution partnerships have been formalised.
The Scorecard Method was developed by Bill Payne, a prominent angel investor and co-founder of the Frontier Angel Fund. It is the most widely used angel valuation method in the United States and has been adapted for international markets including India. The method’s strength lies in its comparative rigour β it benchmarks the subject startup against the median valuation of comparable recently-funded startups, then adjusts upward or downward based on qualitative factors.
Unlike the Berkus Method (which builds value additively from zero), the Scorecard Method starts from a market-derived median and adjusts. This makes it inherently market-anchored, which is an advantage for regulatory defensibility β the valuation is grounded in observable transactions rather than the valuer’s subjective assessment of maximum dimension values.
The Scorecard Method uses six weighted adjustment factors. Each factor is scored relative to the median comparable (100% = at par with median, above 100% = better than median, below 100% = worse). The weighted adjustment factors sum to produce a composite multiplier applied to the median pre-money valuation.
| Factor | Weight | Assessment Criteria |
|---|---|---|
| Strength of Management Team | 30% | Domain expertise, prior startup experience, prior exits, complementary skill sets, full-time commitment, advisory board quality |
| Size of Opportunity | 25% | Total addressable market (TAM), serviceable addressable market (SAM), market growth rate, regulatory tailwinds or headwinds |
| Product / Technology | 15% | Stage of development, technical differentiation, IP protection (patents, trade secrets), prototype functionality |
| Competitive Environment | 10% | Number and strength of direct competitors, barriers to entry, network effects, switching costs |
| Marketing / Sales Channels | 10% | Go-to-market strategy clarity, distribution partnerships secured, early customer acquisition evidence |
| Need for Additional Funding | 5% | Expected burn rate relative to round size, runway post-funding, likelihood of needing a bridge round |
A crucial nuance: the factor scores are not absolute β they are relative to the comparable set. If the median comparable startup has a two-person founding team with five years of domain experience, a target startup with three co-founders and 25 years of combined experience would score 125β140% on the Management factor. Conversely, a solo founder with no domain experience might score 60β70%.
Step 1 β Build the comparable set. We identify 8β12 startups in the same sector, geography (India or South Asia), and stage (pre-revenue or very early revenue) that raised equity funding in the preceding 12β18 months. Sources include Tracxn, Venture Intelligence, Inc42 deal databases, and our proprietary transaction database. We exclude outliers (top and bottom 10% by valuation) to arrive at a robust median.
Step 2 β Determine the median pre-money valuation. From the comparable set, we calculate the median pre-money valuation. For Indian SaaS pre-seed rounds in 2025β2026, this median has ranged from INR 8 crore to INR 15 crore. For D2C brands, INR 5 crore to INR 10 crore. For deep-tech (hardware + software), INR 10 crore to INR 20 crore.
Step 3 β Score each factor. We score each of the six factors relative to the median comparable. The scoring is evidence-based: we require specific documentation for each factor (founder CVs, market research reports, competitive analysis, patent applications, LOIs, financial projections for burn rate analysis).
Step 4 β Calculate the weighted composite factor. The composite factor = sum of (factor weight x factor score). For example, if the Management score is 130% at 30% weight, the contribution is 0.30 x 1.30 = 0.39. Sum all six contributions to get the composite multiplier.
Step 5 β Apply the composite multiplier to the median. Pre-money valuation = Median pre-money x Composite multiplier. If the median is INR 12 crore and the composite multiplier is 1.15, the target startup’s pre-money valuation is INR 13.8 crore.
Consider a fintech startup building an embedded lending platform for e-commerce marketplaces. The company has no revenue, has built an MVP integrated with one marketplace on a sandbox basis, and has a three-person founding team with experience at leading NBFCs and a prior exit.
Comparable set median pre-money valuation (Indian fintech pre-seed, 2025β2026): INR 14 crore.
| Factor | Weight | Score | Weighted Contribution |
|---|---|---|---|
| Management Team | 30% | 135% | 0.405 |
| Size of Opportunity | 25% | 120% | 0.300 |
| Product / Technology | 15% | 110% | 0.165 |
| Competitive Environment | 10% | 85% | 0.085 |
| Marketing / Sales Channels | 10% | 90% | 0.090 |
| Need for Additional Funding | 5% | 100% | 0.050 |
| Composite Multiplier | 1.095 | ||
Pre-money valuation = INR 14 crore x 1.095 = INR 15.33 crore.
The above-median score on Management (prior exit, NBFC experience) and Market Size (embedded lending TAM in India exceeds USD 50 billion by multiple estimates) drives the valuation above the median. The below-median score on Competitive Environment reflects the crowded fintech lending space, tempering the uplift.
Revenue Ramp Bayesian analysis is the most quantitatively rigorous of the three methods and the one we prefer for startups raising Series A-scale pre-revenue rounds (typically INR 5 crore to INR 30 crore). It combines two powerful concepts:
The output is not a single number but a probability-weighted expected value. For regulatory purposes (a FEMA pricing certificate or a Registered Valuerβs report states a single price), we report the expected value (probability-weighted mean) as the fair market value, with the full probability distribution documented in the annexures to the valuation report.
We typically construct four scenarios for a pre-revenue startup:
Scenario 1 β Aggressive Success (probability: 5β15%). The startup achieves product-market fit rapidly, scales revenue aggressively, and reaches a valuation exit or significant follow-on round within 3β4 years. Revenue ramp: zero to INR 50+ crore ARR in 4 years. This scenario assumes everything goes right β strong customer pull, efficient CAC, low churn, successful fundraising at each subsequent round.
Scenario 2 β Moderate Success (probability: 20β30%). The startup achieves product-market fit but takes longer to scale. Revenue ramp: zero to INR 10β20 crore ARR in 4 years. Unit economics are sound but growth is capital-constrained. The startup eventually reaches a modest exit or becomes a sustainable profitable business.
Scenario 3 β Survival / Pivot (probability: 25β35%). The initial product does not achieve strong market fit, but the team pivots to an adjacent opportunity and builds a viable but smaller business. Revenue ramp: zero to INR 2β5 crore ARR in 4 years. Investor returns are modest β capital preservation with minimal upside.
Scenario 4 β Failure (probability: 30β40%). The startup fails to achieve product-market fit, burns through its capital, and winds down. Terminal value is zero or near-zero. The probability assigned to this scenario is anchored to base-rate failure data. For Indian startups at the pre-seed stage, historical failure rates (defined as returning less than 1x capital to investors) are approximately 60β70% according to multiple angel network datasets. We adjust downward from this base rate based on the specific strengths of the subject startup.
Each scenario is valued independently using a DCF methodology. For pre-revenue startups, the DCF within each scenario uses:
The initial (prior) probabilities are assigned based on:
The Bayesian updating mechanism makes this method particularly powerful for milestone-based funding structures. When the startup achieves a specific milestone (e.g., first paying customer, regulatory approval, partnership signing), the probabilities are formally updated. The aggressive success probability increases, the failure probability decreases, and the expected enterprise value rises β justifying a higher share price for the next funding round.
Consider a healthtech startup building an AI-powered diagnostic assistance platform for radiology departments. The company has no revenue, has completed clinical validation at two hospitals, and has received CDSCO approval for its Class B medical device software. The founding team includes a radiologist and two engineers from a leading AI research lab.
| Scenario | Probability | Year 5 Revenue (INR Cr) | Enterprise Value (INR Cr) | PV Today (INR Cr) |
|---|---|---|---|---|
| Aggressive Success | 10% | 80 | 640 | 142.2 |
| Moderate Success | 25% | 18 | 108 | 24.0 |
| Survival / Pivot | 30% | 4 | 16 | 3.6 |
| Failure | 35% | 0 | 0 | 0 |
| Expected Enterprise Value | 21.3 | |||
Probability-weighted expected enterprise value = (10% x 142.2) + (25% x 24.0) + (30% x 3.6) + (35% x 0) = 14.22 + 6.00 + 1.08 + 0 = INR 21.3 crore.
Note how the valuation is dominated by the Aggressive Success scenario despite its low 10% probability β the payoff in that scenario is so large that even a small probability contributes significantly to expected value. This is a fundamental feature of venture investing and explains why angel investors and VCs accept high failure rates.
The discount rate used was 40% (reflecting pre-revenue risk, healthtech regulatory risk, and India-specific risk premiums). The Year 5 exit multiple of 8x revenue (for the Aggressive scenario) is benchmarked to public healthtech SaaS companies listed on Indian and US exchanges, adjusted for a 30% private company discount.
At our practice, we never rely on a single pre-revenue method. Each method has inherent limitations:
We triangulate by applying at least two methods (sometimes all three) and examining the convergence zone. If the Berkus Method yields INR 9 crore, the Scorecard Method yields INR 15 crore, and the Bayesian analysis yields INR 21 crore, we analyse the reasons for divergence and arrive at a justified point estimate within the range. The valuation report documents each method, the triangulation analysis, and the rationale for the final selected value.
For regulatory purposes, the final fair market value stated in the report is typically the value derived from the most defensible method for the specific context. Where a legacy Section 56(2)(viib) assessment is in view (shares issued up to Assessment Year 2024-25), we favour the Bayesian method because it is closest in structure to DCF, the Merchant Banker method under Rule 11UA(2); a pre-revenue method was not itself a prescribed method under that rule. For FEMA NDI pricing, rule 21 names no method, so all three may be used as internationally used venture methods, and the certificate should explain why the method fits the business.
Many valuers default to a standard DCF model for pre-revenue startups. DCF is an accepted method (it was the Merchant Banker method under Rule 11UA(2) and is the most common method under FEMA rule 21), but a DCF that projects revenue from zero to INR 100 crore in five years using a single set of assumptions β without scenario analysis or probability weighting β is intellectually dishonest. The projections are not forecasts in any meaningful sense; they are aspirational targets. A rigorous valuation must acknowledge this uncertainty, either through explicit scenario analysis (as in the Bayesian method) or through wider sensitivity ranges. We have seen Income Tax officers challenge DCF-based valuations where the projected revenue growth was 200% per annum with no supporting evidence β and rightly so.
Founders and investors frequently overestimate the probability of success. Cognitive biases β optimism bias, survivorship bias, overconfidence β are well-documented in entrepreneurial decision-making. A rigorous pre-revenue valuation must anchor to base-rate failure data and then adjust. Ignoring the 60β70% base-rate failure probability for pre-seed startups produces valuations that are systematically inflated. This is not merely an academic concern β an inflated valuation certified by a registered valuer can trigger regulatory scrutiny if it subsequently appears inconsistent with the startup’s trajectory.
The pre-money valuation negotiated between founders and investors is a negotiated commercial term β it reflects supply and demand for the equity, the investor’s portfolio strategy, the founder’s negotiating leverage, and non-financial terms (board seats, liquidation preferences, anti-dilution rights). Fair value in a valuation report, by contrast, is an intrinsic value concept β what a willing buyer would pay a willing seller, both having reasonable knowledge of relevant facts, in an arm’s length transaction. These two concepts can diverge significantly. A startup may negotiate a pre-money valuation of INR 30 crore with a strategic investor who values synergies, while the certified fair value (which excludes synergies) might be INR 15 crore. The valuer must be clear about which concept is being certified.
Pre-revenue valuations are inherently judgemental. The valuer is making assessments about team quality, market size, technology differentiation, and competitive dynamics β none of which can be verified from financial statements. This makes documentation critical. Every assumption must be traced to a source: market research reports, founder interviews, patent filings, LOIs, competitive analysis, comparable transaction data. We maintain a documentation standard of 50+ pages of supporting evidence for each pre-revenue valuation, separate from the valuation report itself. This documentation has proven invaluable when defending valuations before Income Tax officers, FEMA auditors, and investor due diligence teams.
Many pre-revenue startups raise capital through convertible instruments (convertible notes, SAFEs, CCDs, CCPs) rather than equity. The valuation of convertible instruments requires additional analysis β the conversion terms (valuation cap, discount rate, conversion trigger events) affect the fair value of both the convertible instrument and the underlying equity. For a detailed analysis, see our article on Convertible Instruments Valuation in India.
For pre-revenue SaaS startups, the key value drivers are product readiness, integration capability, early beta metrics (if available), and the founding team’s enterprise sales experience. The Berkus dimension of “Prototype / Technology” carries the highest weight because a working product with demonstrated technical capability significantly reduces technology risk. In the Bayesian framework, we model SaaS-specific metrics β projected ARR, net revenue retention, gross margin β within each scenario. The exit multiples are benchmarked to public SaaS companies (both Indian and US-listed), adjusted for India-specific factors.
Deep-tech startups (semiconductors, advanced materials, biotech, quantum computing) face longer development timelines, higher capital requirements, and regulatory approval dependencies. The Bayesian method is most appropriate because the scenario probabilities can be calibrated to regulatory approval success rates (e.g., CDSCO approval rates for medical devices, BIS certification timelines for electronic components). The discount rate for deep-tech is typically 45β55% (higher than SaaS) reflecting the longer time to revenue and the binary nature of regulatory outcomes.
Pre-revenue D2C startups are valued primarily on brand concept, founder’s brand-building track record, and early engagement signals (social media following, waitlist sign-ups, pop-up event sales). The Scorecard Method works well for D2C because there is a relatively deep comparable set of recently-funded Indian D2C brands. The key adjustment factors are product differentiation (can the product be easily replicated?), brand resonance (is there genuine consumer pull?), and unit economics assumptions (is the projected gross margin achievable given input costs and logistics?).
Pre-revenue fintech startups face a unique regulatory dimension β RBI licensing, SEBI registration, or insurance regulatory approval may be a prerequisite for generating any revenue. The Bayesian method is well-suited because regulatory approval can be modelled as a binary gate: scenarios where approval is obtained (and revenue ramp begins) versus scenarios where approval is denied (and the startup must pivot or wind down). The FEMA compliance requirements are particularly relevant for fintech startups receiving FDI, as cross-border fintech regulations are evolving rapidly.
Pre-revenue startups frequently issue Employee Stock Option Plans (ESOPs) to attract talent. The exercise price of ESOPs must be set with reference to the fair market value of the underlying shares. Under Section 17(2)(vi) of the Income Tax Act, the perquisite value of ESOPs at the time of exercise is calculated as the difference between the fair market value on the date of exercise and the exercise price paid by the employee.
For pre-revenue startups, the fair market value of shares at the time of grant is typically low (close to face value if no external funding has occurred). This creates a tax-efficient opportunity: granting ESOPs before the first fundraise locks in a low exercise price. However, if the startup subsequently raises a round at a significant premium, the Assessing Officer may question whether the ESOP exercise price was artificially low. The valuation report supporting the ESOP exercise price must be internally consistent with any concurrent valuation for a share issue. For detailed ESOP valuation guidance, see our article on ESOP Valuation in India.
A pre-revenue valuation report issued by our practice conforms to the ICAI Valuation Standards, 2018 and includes the following sections:
The report is signed by CA V. Viswanathan (IBBI/RV/03/2019/12333) and carries the Virtual Auditor firm stamp. Where the law requires a Merchant Bankerβs valuation, as Rule 11UA(2) did for Section 56(2)(viib) on shares issued up to Assessment Year 2024-25, we coordinate with our partner SEBI-registered Merchant Banker.
🔍 Practitioner Insight β CA V. Viswanathan
In my experience valuing over 200 pre-revenue startups across SaaS, deep-tech, fintech, and D2C verticals, the single most important factor in producing a defensible valuation is the quality of documentation behind each assumption. The methodology matters β Berkus, Scorecard, or Bayesian β but what truly differentiates a valuation that withstands regulatory scrutiny from one that does not is the evidence trail. Every dimension score, every comparable transaction, every probability weight must be traceable to a specific document. When an Assessing Officer questions why a pre-revenue startup was valued at INR 20 crore, the answer cannot be “that is what the method produced.” The answer must be: “here is the comparable set, here is the scoring rationale, here is the base-rate data, and here is how the startup-specific evidence adjusts the outcome.” This is why our valuation reports for pre-revenue startups run 80β120 pages including annexures β not because length equals quality, but because every page serves a specific evidentiary purpose. Founders frequently ask whether they can save costs by obtaining a shorter, simpler valuation certificate. My advice is consistent: the cost of a rigorous valuation (INR 35,000 to INR 75,000 at our practice) is trivial compared to the cost of a FEMA pricing contravention or, for shares issued up to Assessment Year 2024-25, an assessment that adds back the entire share premium as deemed income. Invest in the report upfront. It pays for itself many times over.
| Service | Scope | Fee Range (INR) |
|---|---|---|
| Pre-Revenue Valuation β Registered Valuer report (Single Method) | Berkus or Scorecard with documentation | 35,000 β 40,000 |
| Pre-Revenue Valuation β Registered Valuer report (Multi-Method) | Berkus + Scorecard + Bayesian with triangulation | 45,000 β 75,000 |
| FEMA NDI Pricing Certificate | Floor price determination for FDI round | 35,000 β 60,000 |
| Combined Companies Act + FEMA Valuation | Dual-purpose report for domestic and FDI pricing | 55,000 β 90,000 |
| ESOP Fair Value Certificate (Pre-Revenue) | Exercise price justification with Black-Scholes overlay | 20,000 β 35,000 |
All fees are exclusive of GST at 18%. Turnaround time is 5β7 working days for single-method valuations and 10β12 working days for multi-method valuations with Bayesian analysis. Expedited delivery (3 working days) is available at a 50% surcharge. View detailed pricing or book a consultation.
📋 Key Takeaways
Section 56(2)(viib) (angel tax) does not apply from AY 2025-26, so the company is no longer taxed on share premium received above fair market value, whether the investor is resident or non-resident. The price is still regulated elsewhere. A preferential allotment under Section 62(1)(c) of the Companies Act, 2013 needs a Registered Valuerβs report (Rule 13 of the Companies (Share Capital and Debentures) Rules, 2014). For FDI rounds, rule 21 of the FEMA NDI Rules requires the issue price to be not less than the fair value certified by a Chartered Accountant, SEBI-registered Merchant Banker or practising Cost Accountant. Rule 21 has no separate exemption for DPIIT-recognised startups; a startup company may issue convertible notes to a non-resident for INR 25 lakh or more in a single tranche, with conversion subject to the same pricing rules.
If the Income Tax Assessing Officer challenges the valuation, the most defensible position is a multi-method approach with triangulation. Presenting Berkus, Scorecard, and Bayesian analyses β all pointing to a similar range β demonstrates that the valuation is not dependent on a single set of assumptions. If forced to rely on one method, the Bayesian approach is closest to DCF (the Merchant Banker method under Rule 11UA(2) for Section 56(2)(viib), which applies to shares issued up to AY 2024-25) and has the strongest quantitative foundation. At our practice, we have successfully defended pre-revenue valuations in assessment proceedings by presenting the full methodology with supporting documentation.
The Berkus Method involves qualitative judgement, but this does not make it inherently less defensible than DCF for a pre-revenue startup. A DCF for a company with zero revenue requires projecting revenue from nothing β those projections are equally subjective. The key is documentation: if each Berkus dimension score is supported by specific evidence (comparable transactions, founder track record data, patent filings, LOIs), the subjectivity is bounded and defensible. We have had Berkus-based valuations accepted in both Income Tax and FEMA audit contexts.
We use a build-up method: risk-free rate (Indian 10-year government security yield, currently approximately 7.0β7.2%) + equity risk premium (6β8% for India) + size premium (8β12% for micro-cap / pre-revenue companies) + company-specific risk premium (10β25% depending on stage, team, product, and sector). The total discount rate for pre-revenue startups typically falls in the 35β50% range. This rate is applied within the Bayesian scenario DCFs. Sensitivity analysis showing the valuation at +/- 5% discount rate is included in every report.
Yes, provided the report is structured to address both requirements. For FEMA, the methodology must be internationally accepted and the certificate signed by a Chartered Accountant, SEBI-registered Merchant Banker or practising Cost Accountant (rule 21 of the NDI Rules). Rule 11UA no longer applies to the issuing company, because Section 56(2)(viib) does not apply from AY 2025-26; what remains is the Rule 11UA(1)(c)(b) net-asset value used for Section 56(2)(x) in the recipientβs hands, which the report can state alongside. Our dual-purpose reports include separate sections addressing each regulation’s specific requirements, with a common valuation analysis. This approach saves the client from obtaining two separate reports and ensures internal consistency between the domestic and FDI pricing.
If the startup has less than 6 months of commercial revenue, and the revenue is not yet at a scale that would support meaningful financial projections, pre-revenue methods can still be appropriate. However, the existence of any revenue data provides an additional anchor. We typically use a hybrid approach: the pre-revenue methods (Berkus, Scorecard) are applied alongside a revenue-multiple analysis (even if the revenue base is small) and a DCF with the actual revenue as the starting point. The triangulation across all approaches produces a more robust valuation than any single method.
For FEMA, the pricing certificate must not be more than 90 days old on the date of the investment (RBI Master Direction on Foreign Investment in India, para 8.11). For a preferential allotment under the Companies Act, the Registered Valuerβs report supports the special resolution, and the allotment must be completed within twelve months of that resolution (Rule 13 of the Companies (Share Capital and Debentures) Rules, 2014). Within those limits, material changes in the startup’s circumstances (e.g., achievement of a milestone, change in team composition, shift in market conditions) may necessitate a revised valuation.
Virtual Auditor β AI-Powered CA & IBBI Registered Valuer Firm
Valuer: V. VISWANATHAN, FCA, ACS, CFE, IBBI/RV/03/2019/12333
Chennai (HQ): G-131, Phase III, Spencer Plaza, Anna Salai, Chennai 600002
Bangalore: 7th Floor, Mahalakshmi Chambers, 29, MG Road, Bangalore 560001
Mumbai: Workafella, Goregaon West, Mumbai 400062
Phone: +91 99622 60333 | Email: support@virtualauditor.in
Book a Consultation
Last updated: 16 Nov 2026. Reviewed by CA V. Viswanathan, FCA, ACS, CFE, IBBI Registered Valuer (IBBI/RV/03/2019/12333).